Prevalence and factors associated with hyperkalaemia in stable kidney transplant recipients

Maria Smyrli¹, Pantelis A. Sarafidis², Charalampos Loutradis², Maria Korogiannou³, Ioannis N. Boletis³ and Smaragdi Marinaki³

¹Department of Nephrology, General Hospital of Euaggelismos, Athens, Greece, ²Department of Nephrology, Hippokration Hospital, Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece and ³Clinic of Nephrology and Renal Transplantation, Laiko General Hospital, National and Kapodistrian University, Medical School of Athens, Athens, Greece

Correspondence to: Maria Smyrli; E-mail: mariasmirli3002@hotmail.com

ABSTRACT

Background. Hyperkalaemia is a frequent and potentially life-threatening condition in patients with chronic kidney disease (CKD). Even after successful kidney transplantation (KTx), KTx recipients have mild to severe CKD. Moreover, they share comorbid conditions and frequently use medications that predispose to hyperkalaemia. This study aimed to examine the prevalence and factors associated with hyperkalaemia in this population.

Methods. Over a pre-specified period of 6 months (1 September 2019 to 31 March 2020), we recorded in cross-sectional fashion information on serum potassium (K⁺) and relevant demographics, comorbidities, medications, laboratory and transplant-associated variables in clinically stable KTx recipients attending the Transplant Outpatient Clinic of our Department. Hyperkalaemia was classified as follows: serum K⁺ level >5.0 mEq/L; and further as >5.0 mEq/L with concomitant use of sodium (Na⁺) polystyrene sulphonate; serum K⁺/C21 ≥ 5.2 mEq/L ; serum K⁺/C21 ≥ 5.5 mEq/L. Univariate and multiple logistic regression analyses were used to identify factors associated with serum K⁺ >5.0 mEq/L.

Results. The study population consisted of 582 stable KTx recipients, 369 (63.4%) males, aged 52.4 ± 13.5 years, with estimated glomerular filtration rate (eGFR) of 55.8 ± 20.1 mL/min/1.73 m² transplanted for >1 year. The prevalence of hyperkalaemia defined as K⁺ >5.0 mEq/L; >5.0 mEq/L and use of Na⁺ polystyrene sulphonate; serum K⁺ ≥5.2 mEq/L ; serum K⁺ ≥5.5 mEq/L. Univariate and multiple logistic regression analyses were used to identify factors associated with serum K⁺ >5.0 mEq/L.

Conclusions. The prevalence of mild hyperkalaemia in stable KTx recipients is relatively high but that of moderate or severe hyperkalaemia is low. Among a wide range of factors studied, only male gender and RAAS blockade were associated with increased odds of hyperkalaemia, while higher eGFR and diuretics were associated with decreased odds of hyperkalaemia.
INTRODUCTION

Hyperkalaemia is one of the most frequent electrolyte disorders in clinical practice. Severe hyperkalaemia is a potentially life-threatening condition due to the risk of cardiac conduction abnormalities leading to arrhythmias and sudden death [1, 2]. Hyperkalaemia is relatively rare in the general population but it is considered as an established complication of both acute kidney injury and chronic kidney disease (CKD), especially when estimated glomerular filtration rate (eGFR) is < 60 mL/min/1.73 m² [3–5]. Although low renal function is a cause for potassium (K⁺) elevation per se, in patients with impaired renal function hyperkalaemia is even more aggravated by superimposed factors, such as diabetes mellitus (DM), hyporeninaemic hypoaldosteronism, advanced heart failure (HF) and high dietary K⁺ intake, but most importantly, by the use of medications that increase serum K⁺. These medications include mainly renin–angiotensin–aldosterone system inhibitors and β-blockers, which are essential for the treatment of common comorbid conditions, such as hypertension, proteinuric nephropathy and HF [6–9]. Several lines of evidence suggest that hyperkalaemia is a major factor leading to the use of submaximal doses or discontinuation of RAAS inhibitors (RAASis) and β-blockade in clinical practice [10]. To this end, in recent years two new K⁺-lowering agents were shown to effectively and safely reduce K⁺ levels and are expected to enable more appropriate use of cardioprotective agents [11].

Kidney transplantation (KTxs) is the treatment of choice for patients with end-stage renal disease (ESRD), as it is associated with at least 2-fold higher life expectancy and improved quality of life compared with renal replacement therapy. Despite a substantial improvement in renal function, the vast majority of transplanted patients do not reach a normal GFR. Further, they still have a higher burden of comorbid conditions and higher risk of cardiovascular morbidity and mortality compared with the general population [12, 13]. Factors like post-transplant DM (PTDM), increased appetite leading to high K⁺ intake and need for use of cardioprotective medications such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers and aldosterone receptor antagonists, combined with the use of immunosuppressive agents, such as cyclosporine and tacrolimus, are all factors that can interfere with K⁺ homeostasis, also in KTxs recipients [14, 15].

Despite the fact that the KTxs recipients share many common factors contributing to hyperkalaemia with patients with pre-dialysis CKD, studies investigating the impact of hyperkalaemia in KTxs are scarce and small, while relatively larger studies have been conducted in order to assign more specific questions. For example, a retrospective study evaluated the relationship between the use of cyclosporine and tacrolimus with hypokalaemia and hyperkalaemia in 25 KTxs recipients [16], a cross-sectional study examined the prevalence and the causes of renal tubular acidosis (RTA) in the late transplantation period [17], while the largest study in the field evaluated the impact of ACEIs and ARBs on the incidence of hyperkalaemia [18]. Therefore, we aimed to assess in a cross-sectional fashion the prevalence and potential determinants of hyperkalaemia.
among a wide set of demographic, clinical and laboratory characteristics in a population of KTx recipients followed in a KTx Clinic of a tertiary University Hospital.

MATERIALS AND METHODS

Study design and patients

This is a cross-sectional study in stable KTx recipients who were under regular follow-up in the Transplantation Outpatient Clinic of Laiko General Hospital, Athens, Greece. This Nephrology and Renal Transplantation Clinic is the largest transplantation centre in Greece, performing up to 80–90 KTx annually.

KTx recipients are regularly attending the outpatient clinic at intervals ranging from 1 week to 6 months. At every visit, a complete routine haematological and biochemical laboratory work up, including serum K⁻, as well as target trough levels of immunosuppressive medications, is performed. All immunosuppressive and concomitant medications, patients’ weight and blood pressure (BP) are also monitored and recorded at every visit.

For the purpose of this study, we collected data at a single time point (i.e. at the first scheduled visit during a pre-specified period of 6 months from 1 September 2019 to 31 March 2020) for all clinically stable KTx recipients, regularly attending the outpatient transplant clinic, who had completed at least 1 year from surgery and had complete information for the main variables of interest. The study protocol was approved by the Institutional Review Board of the Laiko General Hospital.

Data collection

All study data for each subject were recorded during the scheduled visit on the relevant patient charts and were transferred to a purpose-built electronic data-collecting sheet. We collected routine data on demographics (gender, age at the time of transplantation as well as age at the date of the examination, height and weight for the calculation of body mass index (BMI)]; cause of ESRD; previous dialysis vintage; comorbidities (hypertension, diabetes, coronary heart disease, stroke, HF, liver disease, chronic obstructive pulmonary disease and peripheral artery disease); and routine haematological and biochemical parameters [K⁻, sodium (Na⁺), urea, creatinine, etc.], for each participant. We also recorded information related to KTx such as ABO incompatibility between donor and recipient, human leukocyte antigen (HLA) sensitization, donor age, age difference between donor and recipient, presence of PTDM, graft origin (deceased or living) and trough levels of calcineurin inhibitors (CNIs) and mammalian target of rapamycin inhibitors (mTORis). We recorded the current immunosuppressive regimens consisting of CNIs (tacrolimus, and less often cyclosporine), antimetabolites, mTORis and corticosteroids. Additionally, we collected information on concomitant medications, including those that interfere with K⁻ regulation, such as ACEIs, ARBs, renin inhibitors, aldosterone blockers (spironolactone and eplerenone), β-blockers, thiazide diuretics, loop diuretics, non-steroidal anti-inflammatory drugs or cyclooxygenase inhibitors, oral hypoglycaemic agents and insulin, heparin, trimethoprim, pentamidine, digoxin, resin K⁺ exchangers and Na⁺ bicarbonate.

Definitions

For reasons of relevance to common clinical practice and in accordance with previous studies, hyperkalaemia was classified as follows: serum K⁺ level >5.0 mEq/L and further as: serum K⁺ >5.0 mEq/L with concomitant use of Na⁺ polystyrene sulphonate; serum K⁺ >5.2 mEq/L; and serum K⁺ >5.5 mEq/L. Hypokalaemia was defined as serum K⁺ <3.5 mEq/L. In addition to the above hyperkalaemia thresholds, we examined the percentage of patients with serum K⁺ levels <3.5, ≥3.5 to ≤5.0, >5.0 to <5.5 and ≥5.5 mEq/L. eGFR was calculated with the use of the CKD Epidemiology Collaboration equation [19].

Statistical analysis

Statistical analysis was performed with Statistical Package for Social Sciences version 23 (SPSS Inc., Chicago, IL, USA). The normality of distribution for quantitative variables was examined using the Kolmogorov-Smirnov test. Continuous variables are expressed as mean ± standard deviation or median (interquartile range) according to normality of the distribution; categorical variables are presented as absolute and relevant frequencies. Comparisons for quantitative parameters with the Student’s t-test or the Mann–Whitney test and for qualitative parameters were performed with the chi-square or the Fisher’s exact tests. Univariate and multivariable logistic regression analyses were performed in the total study population to evaluate the effect of various parameters possibly interfering with K⁻ homeostasis with the threshold for the definition of hyperkalaemia set at >5.0 mEq/L. Variables were tested for interactions and included in the multivariable model if P < 0.2 in univariate analysis. Odds ratios (ORs) are reported with 95% confidence intervals (CIs). Probability values of P < 0.05 (two-tailed) were considered statistically significant in all comparisons.

RESULTS

Demographic and clinical characteristics

Of a total of 668 patients that had a scheduled appointment during the pre-specified period, 58 patients were excluded as they had less than a year from KTx surgery during their regular appointment; another 23 patients were excluded as they missed their clinic appointments during the pre-specified follow-up period, while 3 patients restarted dialysis and 2 more patients died before their clinic visit (Figure 1). Thus, the final study population consisted of 582 patients, the clinical and demographic characteristics of whom are shown in Table 1. From the total cohort, 369 patients were males (63.4%), the
mean age was 52.4 ± 13.5 years, mean eGFR 55.8 ± 20.1 mL/min/1.73 m² and dialysis vintage before KTx 4.7 ± 4.1 years.

### Prevalence of hyperkalaemia

The mean K⁺ level in our patient cohort was 4.63 ± 0.48 mEq/L. The prevalence of hyperkalaemia defined as serum K⁺ >5.0 mEq/L in the overall population was 22.7% (132 out of total 582 patients). Only four patients were on Na⁺ polystyrene sulphonate, all of whom had serum K⁺ >5.0 mEq/L; thus the prevalence of hyperkalaemia, defined as K⁺ >5.0 mEq/L and concomitant use of Na⁺ polystyrene sulphonate, was again 22.7%. The prevalence of hyperkalaemia defined as K⁺ >5.2 mEq/L and >5.5 mEq/L was 14.4% (84 patients) and 4.1% (24 patients), respectively. No patient had serum K⁺ levels ≥6.0 mEq/L.

The distribution of serum K⁺ levels in the population studied is shown in Figure 2. Overall, only two patients (0.3%) had K⁺ levels <3.5 mEq/L. Another 77.0% had normal K⁺ levels (≥3.5 to <5.0 mEq/L), whereas 18.6 and 4.1% had serum K⁺ levels >5.0 to <5.5 mEq/L and ≥5.5 mEq/L, respectively.

### Factors associated with hyperkalaemia

In univariate comparisons (Table 1), individuals with serum K⁺ >5.0 mEq/L were more often males, compared with those with
K⁺ ≤ 5.0 mEq/L (77.2% versus 60.7%, P = 0.011). The two groups did not differ significantly with respect to age, BMI, dialysis vintage, burden of comorbidities and primary cause of kidney disease. Systolic and diastolic BP (SBP and DBP) levels were also comparable between groups. However, as shown in Table 1, a number of differences between groups were noted in routine biochemistry parameters, with patients with high K⁺ having significantly higher levels of serum creatinine and lower eGFR (48.3 ± 18.1 ml/min/1.73 m² versus 58.0 ± 20.1 ml/min/1.73 m², P < 0.001) than those with normal K⁺. In addition, there were subtle but significant differences in serum Na⁺, phosphate and glucose (101.6 ± 22.5 mg/dL versus 98.8 ± 21.1 mg/dL, P < 0.003).

Table 2 presents information on the use of medications, including those interfering with K⁺ homeostasis. The use of ACEIs (27.3% versus 18.2%, P = 0.023) was more common and that of ARBs (11.4% versus 6.7%, P = 0.076) marginally more common among patients with high K⁺. In contrast, the use of thiazide and loop diuretics was less common (3.0% versus 10.9%, P = 0.006). As discussed above, only four patients, all in the high K⁺ group, were using Na⁺ polystyrene sulphonate. The proportion of patients using β-blockers, insulin oral hypoglycaemic agents, heparin, Na⁺ bicarbonate and β-agonists did not differ between groups. Of note, none of the study subjects was receiving a renin inhibitor, torsemide, non-steroidal anti-inflammatory drugs or pentamidine at the time of the study.

With regards to transplantation-related factors (Table 3), there were no differences between the two groups either in means of donor and recipient age or donor–recipient age difference, or in the time since transplantation. Similarly, renal allograft origin (deceased or living), ABO incompatibility, HLA sensitization and development of PTDM were similar between the groups. In addition, immunosuppressive drugs such as steroids, cyclosporine, tacrolimus and mycophenolate mofetil, as well as levels of both CNIs, did not differ between groups. Considering immunosuppressive drugs, the only difference observed was that patients with elevated K⁺ levels were less likely to receive mTORis compared with those with serum K⁺ ≤ 5.0 mEq/L (3.8% versus 11.1%, P = 0.011).

Additionally, we performed multiple logistic regression analysis including serum K⁺ > 5.0 mEq/L as the dependent variable and several demographic, clinical and laboratory factors that were previously identified from univariate analyses as independent variables. As shown in Table 4, in multivariate analysis age, BMI, comorbidities, cause of ESRD and dialysis vintage, and most of the drugs examined were not associated with higher odds of hyperkalaemia. This was also the case for transplantation-related factors, such as donor and recipient age, time since transplantation, immunological risk and immunosuppressive therapy. Thus, the only variables that were independently associated with higher odds of hyperkalaemia in multivariate analysis were male gender (adjusted OR = 2.020, 95% CI 1.264–3.227) and use of RAASis (including ACEIs, ARBs and aldosterone blockers) (adjusted OR = 1.628, 95% CI 1.045–2.536), while higher eGFR (adjusted OR = 0.967, 95% CI 0.955–0.979) and non-K⁺-sparring diuretic use were associated with lower odds of hyperkalaemia (OR = 0.140, 95% CI 0.046–0.430).

**FIGURE 2:** Distribution of serum K⁺ levels in the study population.

**DISCUSSION**

This study was designed to examine the prevalence of hyperkalaemia in KTx recipients and to evaluate possible associations with factors that may contribute to its occurrence. The prevalence of hyperkalaemia in the current population examined at the > 5.0 mEq/L threshold was ~ 23%, while only 4.1% had K⁺ levels ≥ 5.5 mEq/L. These results suggest that mild hyperkalaemia is common but moderate to severe hyperkalaemia uncommon in stable KTx recipients. Among a wide range of demographic, clinical and laboratory characteristics examined, only a small set of factors were independently associated with hyperkalaemia. Male gender and use of RAASis were associated with higher odds, while higher eGFR and thiazide or loop diuretic use were associated with lower odds of the disorder. None of the factors associated with the process and medications for transplantation affected the occurrence of hyperkalaemia. In KTx recipients, there is a paucity of studies evaluating the overall prevalence and the determinants of hyperkalaemia. Most studies in the field examine specific issues, or patients during the early post-transplant period. Experimental models have shown that both CNIs increase K⁺ levels by inhibiting the Na⁺/K⁺/ATPase in the luminal K⁺ channels; moreover, an over activation of the Na⁺/K⁺/2Cl co-transporter of the distal tubule by tacrolimus but not by cyclosporine has been described [20]. Higgins retrospectively studied 125 KTx recipients during the early (first 90 days after transplantation) transplantation period comparing the impact of the two CNIs on Na⁺ and K⁺ levels. Serum K⁺ levels were significantly higher in recipients receiving tacrolimus compared with those receiving cyclosporine and this effect was even more prominent among those with concomitant hyponatraemia [16]. Given the fact that in the modern immunosuppressive era tacrolimus has almost uniformly replaced cyclosporine with > 90% of KTx recipients being discharged on Tac-based immunosuppression nowadays, head-to-head comparison studies between the two CNIs on specific side effects are almost absent [21].

Another study evaluated the impact of various trough levels of tacrolimus during the very early (2 weeks) post-transplant period in a cohort of 816 KTx recipients. Primary outcomes included delayed graft function and length of stay and secondary outcomes hyperkalaemia and biopsy-proven acute rejection. Though tacrolimus levels were high (> 10 mg/mL) in three of the four groups investigated, there was no difference in the rates of hyperkalaemia (which were 24, 27 and 26%, respectively) between groups. Of note, the threshold for hyperkalaemia in this study was set at 6.0 mEq/L [22]. During the late (> 12 months
after transplantation) post-transplant period one cross-sectional study examined the prevalence and risk factors for RTA in a cohort of 576 stable KTx recipients with well-preserved renal function. RTA was found in 76 out of 576 patients (13%). Hyperkalaemia was present in a total of 32 patients, 11 with distal RTA subtype Ib (hyperkalaemic) and 21 with subtype IV distal RTA. Interestingly, this study also showed higher association of tacrolimus-based compared with cyclosporine-based immunosuppression with the development of RTA [17]. Finally, Mitterbauer et al. conducted a cohort study in 2041 KTx recipients that did not assess hyperkalaemia prevalence, but longitudinally compared serum K⁺ levels between subjects with versus without ACEI/ARB therapy using a mixed-effects general linear model. The overall adjusted estimated serum K⁺ difference between recipients with versus without ACEI/ARB therapy was 0.08 mmol/L (P < 0.001), while diuretics were associated with a

| Parameter | K⁺ ≤5.0 mEq/L | K⁺ >5.0 mEq/L | P-value |
|-----------|---------------|---------------|---------|
| N (%)     | 450 (77.3)    | 132 (22.7)    | –       |
| ACEIs     | 82 (18.2)     | 36 (27.3)     | 0.023   |
| ARB       | 30 (6.7)      | 15 (11.4)     | 0.076   |
| CCBs      | 163 (36.2)    | 40 (30.3)     | 0.210   |
| β-blockers| 31 (6.9)      | 16 (12.1)     | 0.052   |
| Centrally active | 17 (3.8) | 6 (4.5) | 0.691 |
| Oral hypoglycaemic agents | 26 (5.8) | 5 (3.8) | 0.371 |
| Insulin   | 17 (3.8)      | 9 (6.8)       | 0.137   |
| Cinacalcet| 83 (18.4)     | 24 (18.2)     | 0.945   |
| Vitamin D analogues | 128 (28.4) | 42 (31.8) | 0.454 |
| EPO       | 26 (5.8)      | 10 (7.6)      | 0.451   |
| Heparin   | 3 (0.7)       | 2 (1.5)       | 0.318   |
| Trimethoprim | 8 (1.8) | 3 (2.3) | 0.719 |
| Digoxin   | 1 (0.2)       | 0 (0.0)       | 1.000   |
| Na⁺-polystyrene sulphonate | 0 (0.0) | 4 (3.0) | 0.003 |
| Statins   | 94 (20.9)     | 24 (18.2)     | 0.496   |
| Na⁺ bicarbonate | 9 (6.8) | 23 (4.0) | 0.055 |
| β2-agonists | 2 (1.5) | 3 (2.5) | 0.130 |
| Clopidogrel| 1 (0.8)      | 14 (2.4)      | 0.209   |
| Aspirin   | 48 (10.7)     | 12 (9.1)      | 0.601   |
| NOACs     | 23 (5.1)      | 7 (5.3)       | 0.930   |

Probability values of P < 0.05 were considered statistically significant in all comparisons are in bold. Data are presented as n (%). CCBs, calcium channel blockers; EPO, erythropoietin; NOACs, novel oral anticoagulants.

| Parameter | Total population | K⁺ ≤5.0 mEq/L | K⁺ >5.0 mEq/L | P-value |
|-----------|-----------------|---------------|---------------|---------|
| Age when transplanted, years | 44.8 ± 13.4 | 45.1 ± 13.5 | 43.9 ± 12.9 | 0.377 |
| Years since transplantation, years | 5.2 [9.1] | 5.3 [8.7] | 4.6 [10.8] | 0.644 |
| Donors age, years | 52.5 ± 14.2 | 52.4 ± 14.2 | 53.2 ± 14.3 | 0.557 |
| Difference between donors’ and recipients’ ages, years | 7.9 [26.3] | 7.0 [26.7] | 9.9 [25.4] | 0.217 |
| Deceased origin, n (%) | 166 (28.5) | 128 (28.4) | 38 (28.8) | 0.939 |
| Sensitization, n (%) | 29 (5.0) | 24 (5.3) | 5 (3.8) | 0.473 |
| ABO incompatibility, n (%) | 14 (2.4) | 11 (2.4) | 3 (2.3) | 0.910 |
| PTCM, n (%) | 44 (9.8) | 14 (10.6) | 58 (10.0) | 0.780 |
| Steroids, n (%) | 539 (95.5) | 420 (93.3) | 119 (90.2) | 0.219 |
| Tacrolimus, n (%) | 483 (83.0) | 376 (83.6) | 107 (81.1) | 0.502 |
| Cyclosporine, n (%) | 53 (9.1) | 36 (8.0) | 17 (12.9) | 0.087 |
| Mycophenolate mofetil, n (%) | 556 (95.5) | 428 (95.1) | 128 (97.0) | 0.363 |
| mTORi, n (%) | 55 (9.5) | 50 (11.1) | 5 (3.8) | 0.011 |
| Tacrolimus levels, ng/mL | 6.2 [1.6] | 6.2 [1.7] | 6.3 [1.7] | 0.111 |
| Cyclosporine C0 levels, ng/mL | 159.6 ± 60.9 | 156.5 ± 56.3 | 165.2 ± 69.6 | 0.592 |
| Cyclosporine C2 levels, ng/mL | 521.6 ± 171.9 | 499.9 ± 172.8 | 561.0 ± 167.1 | 0.183 |
| mTORi levels, ng/mL, n (%) | 5.5 ± 1.1 | 5.5 ± 1.2 | 5.5 ± 0.7 | 0.977 |

Probability values of P < 0.05 were considered statistically significant in all comparisons are in bold. Normally distributed variables are presented as mean ± standard deviation, non-normally distributed variables as median [interquartile range] and categorical variables as absolute frequency (proportion).
Table 4. Univariate and multivariate analysis of factors possibly associated with serum K⁺ >5.0 mEq/L in the total study population

| Parameter                              | Univariate analysis | Multivariate analysis |
|----------------------------------------|---------------------|-----------------------|
|                                        | Unadjusted OR       | 95% CI                | P-value | Adjusted OR       | 95% CI                | P-value |
|                                        | OR                   | CI                    |         | OR                   | CI                    |         |
| Age, years                             | 0.997               | 0.983–1.011           | 0.668   | 2.020               | 1.264–3.227           | 0.003   |
| Male gender                            | 1.729               | 1.128–2.650           | 0.012   |                      |                      |         |
| BMI, kg/m²                              | 0.979               | 0.929–1.031           | 0.423   |                      |                      |         |
| Dialysis vintage, years                | 1.011               | 0.966–1.058           | 0.638   |                      |                      |         |
| Hypertension                           | 0.996               | 0.667–1.485           | 0.983   |                      |                      |         |
| DM                                     | 2.175               | 0.699–6.765           | 0.179   |                      |                      |         |
| Dyslipidaemia                          | 0.998               | 0.625–1.595           | 0.994   |                      |                      |         |
| CAD                                    | 0.644               | 0.280–1.483           | 0.301   |                      |                      |         |
| HF with reduced EF                     | 2.492               | 0.778–7.984           | 0.124   | 3.283               | 0.876–12.305          | 0.078   |
| COPD                                   | 1.727               | 0.512–5.826           | 0.379   |                      |                      |         |
| eGFR (mL/min/1.73 m² increase)         | 0.973               | 0.963–0.984           | <0.001  | 0.967               | 0.955–0.979           | <0.001  |
| Years since transplantation, years     | 1.012               | 0.985–1.039           | 0.391   |                      |                      |         |
| Sensitization                         | 0.699               | 0.261–1.869           | 0.475   |                      |                      |         |
| CNIs                                   | 1.430               | 0.650–3.145           | 0.374   |                      |                      |         |
| Steroids                               | 0.654               | 0.331–1.293           | 0.222   |                      |                      |         |
| Mycophenolate mofetil                  | 1.645               | 0.557–4.861           | 0.368   |                      |                      |         |
| Oral hypoglycaemic agents              | 0.642               | 0.242–1.706           | 0.374   |                      |                      |         |
| Insulin                                | 1.864               | 0.811–4.284           | 0.143   | 1.227               | 0.481–3.132           | 0.668   |
| RAASi                                  | 1.735               | 1.152–2.615           | 0.008   | 1.628               | 1.045–2.536           | 0.031   |
| Diuretics                              | 0.256               | 0.091–0.722           | 0.010   | 0.140               | 0.046–0.430           | 0.001   |
| β-blockers                             | 0.836               | 0.550–1.271           | 0.401   |                      |                      |         |
| Heparin                                | 2.292               | 0.379–13.865          | 0.366   |                      |                      |         |
| Na⁺ bicarbonate                       | 2.279               | 0.963–5.390           | 0.061   | 1.475               | 0.588–3.702           | 0.408   |
| β2-agonists                            | 6.908               | 0.621–76.785          | 0.116   | 8.325               | 0.414–167.237         | 0.166   |

Probability values of P<0.05 were considered statistically significant in all comparisons are in bold. CAD, coronary artery disease; COP D, chronic obstructive pulmonary disease; EF, ejection fraction.

0.11 mmol/L (P<0.001) lower K⁺ and each GFR decrease by 10 mL/min led to an increase of 0.04 mmol/L (P<0.001) [18].

The prevalence of hyperkalaemia in pre-dialysis CKD patients has been examined more thoroughly. In a cross-sectional analysis of electronic medical records involving 1216 individuals with eGFR values of 30–60, 15–30 and <15 mL/min/1.73 m², the prevalence of serum K⁺ >5.0 mEq/L rose from ~10% to 18% and 22%, respectively [23]. In a cohort study of 1038 patients with CKD, the prevalence of hyperkalaemia (serum K⁺ >5.0 mEq/L or intake of ion exchange resin) was at 17% for the total population, increasing from 2% to 42% as eGFR decreased from >60 to <20 mL/min/1.73 m²; in multivariate analysis, male gender and use of RAASIs were independently associated with hyperkalaemia [24]. In a study of 238 outpatients followed in a low-clearance clinic with a mean eGFR of 53.8, 31.5 and 8.5% for serum K⁺ levels of >5.0, >5.5 and >6.0 mEq/L, respectively, was reported, while an eGFR <15 mL/min/1.73 m² was independently associated with hyperkalaemia [4]. In a population of 360 CKD patients with an average eGFR at 43 mL/min/1.73 m², hyperkalaemia (serum K⁺ >5.0 mmol/L or intake of ion exchange resin) was at 21.7%, while CKD Stage 4, smoking and ACEI use were all associated with increased odds of hyperkalaemia [8]. Another study of about 13 500 patients with eGFR <60 mL/min/1.73 m², concluded that for every 5 mL/min/1.73 m² drop in eGFR, patients had a 26% higher risk for hyperkalaemia (defined as K⁺ >5.5 mEq/L) [25]. Our findings suggest a prevalence of hyperkalaemia slightly higher than most of the abovementioned studies, i.e. 22.7% at the >5.0 mEq/L threshold for a population with an average eGFR at 56 mL/min/1.73 m²; however, the occurrence of moderate hyperkalaemia (>5.5 mEq/L) was low. In addition, our findings in multivariate analysis are largely consistently associated with the previous results, showing that male gender and RAASIs were associated with higher odds, and preserved eGFR with lower odds of hyperkalaemia, respectively.

To the best of our knowledge, this is the first cross-sectional study assessing the prevalence and determinants of hyperkalaemia in a large cohort of stable KTx recipients at the long-term post-transplantation period. The study was carefully designed in order to assess a wide range of demographic, laboratory and biochemical factors that could affect K⁺ levels. Furthermore, it evaluated simultaneously all medications known to affect K⁺ regulation and several factors relevant to KTx that may also interfere. However, this is a cross-sectional analysis, thus we could not establish cause and effect associations between hyperkalaemia and the factors examined. The cross-sectional design also did not allow us to assess whether previous medical decisions (i.e. discontinuation of ACEIs or ARBs, switch in immunosuppression, prescription of diuretics or Na⁺ bicarbonate administration) aiming to change serum K⁺ levels had preceded the current investigation; in any case, the study aimed to capture the actual reality of everyday clinical practice. Finally, our study was carried out in a single centre; though we believe our sample is representative of the average KTx recipient of a European transplant centre, it is not clear whether our observations could be generalizable to other KTx populations with largely different dietary habits, or treatment strategies.

In conclusion, this study shows that hyperkalaemia is rather frequent in stable KTx recipients. However, moderate and severe hyperkalaemia are rather rare, a fact likely related to the well-preserved renal function in the vast majority of patients. Among a large set of demographic, clinical and laboratory factors examined, the parameters independently associated with hyperkalaemia were male gender and RAASIs.
Hyperkalaemia in this population were largely similar to those in patients with CKD, i.e. male gender and RAASIs were associated with higher odds, while preserved eGFR and common diuretics (thiazide and loop diuretics) with lower odds of hyperkalaemia, while there was no impact of any immunosuppressive agent on serum K⁺ levels. Longitudinal studies are warranted to evaluate the possible influence of hyperkalaemia on the choice of and the adherence to recommended medications, such as RAASIs, and its association with morbidity and mortality in this patient population.

**FUNDING**
This study was not supported by any source and represents the original effort of the authors.

**AUTHORS’ CONTRIBUTIONS**
Study conception and design were carried out by P.A.S., I.N.B. and S.M.; data acquisition was done by M.S. and M.K.; statistical analysis was performed by C.L.; data interpretation was carried out by M.S. and P.A.S.; manuscript drafting was done by M.S., P.A.S. and S.M.; supervision and mentorship were provided by I.N.B. and S.M. All authors have read and agreed to the published version of the manuscript.

**CONFLICT OF INTEREST STATEMENT**
None of the authors has any conflict of interest to disclose.

**DATA AVAILABILITY STATEMENT**
The data underlying this article will be shared on reasonable request to the corresponding author.

**REFERENCES**
1. Weiner ID, Wingo CS. Hyperkalemia: a potential silent killer. J Am Soc Nephrol 1998; 9: 1535–1543
2. Palmer BF. A physiologic-based approach to the evaluation of a patient with hyperkalemia. Am J Kidney Dis 2010; 56: 387–393
3. Acker CG, Johnson JP, Palevsky PM et al. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 1998; 158: 917–924
4. Sarafidis PA, Blacklock R, Wood E et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol 2012; 7: 1234–1241
5. Einhorn LM, Zhan M, Hsu VD et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009; 169: 1156
6. Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol 2014; 34: 333–339
7. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000; 109: 307–314
8. Loutradis C, Tolika P, Skodra A et al. Prevalence of hyperkalemia in diabetic and non-diabetic patients with chronic kidney disease: a nested case-control study. Am J Nephrol 2015; 42: 351–360
9. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 2010; 5: 531–548
10. Pappoe LS, Winkelmayer WC. ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized? Drugs Aging 2010; 27: 87–94
11. Sarafidis PA, Georgiannos PI, Bakris GL. Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opin Pharmacother 2015; 16: 2205–2215
12. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725–1730
13. Meier-Kriesche HU, Schold JD, Srinivas TR et al. Kidney transplantation Halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4: 1662–1668
14. Pochineni V, Rondon-Berrios H. Electrolyte and acid-base disorders in the renal transplant recipient. Front Med (Lausanne) 2018; 5: 261
15. De Waele L, Van Gaal PJ, Abramowicz D. Electrolytes disturbances after kidney transplantation. Acta Clin Belg 2019; 74: 48–52
16. Higgins R. Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities. Nephrol Dial Transplant 2004; 19: 444–450
17. Schwarz C, Benesch T, Kodras K et al. Complete renal tubular acidosis late after kidney transplantation. Nephrol Dial Transplant 2006; 21: 2615–2620
18. Mitterbauer C, Heinze G, Kainz A et al. ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations. Nephrol Dial Transplant 2008; 23: 1742–1746
19. Levey AS, Stevens LA, Schmid CH et al.; for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612
20. Mohebbi N, Mihailova M, Wagner CA. The calcineurin inhibitor FK506 (tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport proteins. Am J Physiol Renal Physiol 2009; 297: F499–F509
21. Lim MA, Kohli J, Bloom RD. Immunosuppression for kidney transplantation: where are we now and where are we going? Transplant Rev (Orlando) 2017; 31: 10–17
22. Andreoni K. Effect of different tacrolimus levels on early outcomes after kidney transplantation. Ann Transplant 2014; 19: 68–75
23. Drion I, Joosten H, Dikkeschei LD et al. eGFR and creatinine clearance in relation to metabolic changes in an unselected patient population. Eur J Intern Med 2009; 20: 722–727
24. Moranne O, Frossart M, Rossert J et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 2009; 20: 164–171
25. Drawz PE, Babineau DC, Rahman M. Metabolic complications in elderly adults with chronic kidney disease. J Am Geriatr Soc 2012; 60: 310–315